Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VSA006 · 1 trial · 1 indication
No Worsening of NASH is defined as no increase in inflammation, ballooning, or steatosis scores in the NAS score.
NASH Improvement indicates a reduction by at least 2 points in the NAS score, with at least one-point reduction in ballooning without increase in steatosis score.
| Arm | Type | Description |
|---|---|---|
| VSA006 low dose | EXPERIMENTAL | - |
| VSA006 low dose comparator | PLACEBO_COMPARATOR | - |
| VSA006 high dose | EXPERIMENTAL | - |
| VSA006 high dose comparator | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VSA006 | DRUG | every 12 weeks, subcutaneous injections |
| Placebo | DRUG | every 12 weeks, subcutaneous injections |
Inclusion Criteria: * body mass index (BMI) of 24-35 kg/m2 ; * NASH patients confirmed by liver histopathology: NAS score is ≥ 4 and CRN fibrosis is F2 or F3 ; * At screening, ALT is \> ULN; * At screening, the liver fat content measured by MRI-PDFF is ≥ 8%; * Weight change \< 5% at least 3 months ...
VSA006 is an investigational drug being developed for the treatment of nonalcoholic steatohepatitis (NASH), a form of fatty liver disease. It is currently being evaluated in a Phase 2 clinical trial specifically in Chinese patients with NASH.
VSA006 targets HSD17B13, an enzyme involved in lipid metabolism that has been linked to liver disease. By modulating this target, VSA006 aims to address the underlying pathology of NASH. The drug is being studied for its efficacy and safety in patients with this condition.
VSA006 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company. The company is conducting a Phase 2 clinical trial to evaluate the drug's efficacy and safety in patients with NASH.
VSA006 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is designed to assess its efficacy and safety in patients with NASH.
VSA006 is being studied in a Phase 2 clinical trial with the identifier NCT06322628. This trial is titled 'A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients' and is currently active but not recruiting participants. The trial is randomized, double-blind, and placebo-controlled, with an enrollment of 48 patients.